Clinical study of autologous adipose derived mesenchymal stem cells alone or in combination with small molecule drugs in the treatment of osteoarthritis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036958

Enrollment

Unknown

Registered

2020-08-25

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Group 1:etoricoxib + placebo

Group 2:Etoposide and metformin 1000mg

Group 3:Etoposide and metformin 2000mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female aged 35-70 years; 2. Accord with the diagnosis of knee osteoarthritis.

Exclusion criteria

Exclusion criteria: 1. Osteoarthritis with K-L grade less than 2 or above 2. Inflammatory joint diseases (rheumatoid arthritis, psoriatic arthritis, etc.) 3. Complicated with any infection, including skin infection, or with symptoms and signs of infection or fever. 4. Immune system deficiency status, such as diabetes, cancer, AIDS. 5. Other cases requiring immunosuppressive drugs; 6. Long term use of non steroidal anti-inflammatory and analgesic drugs; 7. History of ipsilateral or contralateral knee surgery; 8. Patients who cannot be examined with MRI.

Design outcomes

Primary

Measure	Time frame
MRI;telomerase;Methylation;Knee function score;	—

Secondary

Measure	Time frame
Weigh;	—

Countries

China

Contacts

Public ContactZhang Xiaoling

Xinhua Hospital Aflliated to Shanghai Jiao Tong University School of Medicine

xlzhang@shsmu.edu.cn+86 13564636096

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026